Csa Biotechnologies
CSA BioTech is a clinical stage therapeutic development company focused on developing ceragenin-based therapeutics. They aim to provide a superior defense against drug-resistant infections and diseases by harnessing the body's innate immune system with their platform technology of ceragenins, which are synthetic small molecules mimicking endogenous antimicrobial peptides. Their mission is to create safe, effective, and scalable antimicrobial and regenerative agents to combat resistant pathogens, promote tissue repair, and improve health outcomes.
Industries
Nr. of Employees
small (1-50)
Csa Biotechnologies
Spanish Fork, Utah, United States, North America
Products
Therapeutic candidates based on cationic small-molecule peptide mimetics
Clinical-stage therapeutic candidates derived from a platform of small-molecule, membrane-active mimetics of host-defense peptides intended for treatment of chronic wounds and other indications.
Topical and device-directed antifungal formulations
Formulated gel and cream candidates intended for topical eradication of fungal infections in skin and mucosal tissues, evaluated in ex vivo and in vitro models.
cholic acid derivatives
A series of cholic acid derivatives designed to mimic the activities of polymyxin B and its derivatives, acting as potent antibiotics and effective permeabilizers of the outer membranes of gram-negative bacteria. Some compounds rival polymyxin B in antibacterial activity against gram-negative and gram-positive bacteria and can synergistically interact with hydrophobic antibiotics to inhibit bacterial growth.
Ceragenins
Synthetic small molecules designed to mimic key properties of antimicrobial peptides such as cathelicidins. Non-peptide structures offering advantages in drug development, formulation, and stability.
CAV-121
An investigational ceragenin-based therapeutic candidate being developed for Epidermolysis Bullosa, informed by innate immune biology and antimicrobial peptide-inspired science.
Therapeutic candidates based on cationic small-molecule peptide mimetics
Clinical-stage therapeutic candidates derived from a platform of small-molecule, membrane-active mimetics of host-defense peptides intended for treatment of chronic wounds and other indications.
Topical and device-directed antifungal formulations
Formulated gel and cream candidates intended for topical eradication of fungal infections in skin and mucosal tissues, evaluated in ex vivo and in vitro models.
cholic acid derivatives
A series of cholic acid derivatives designed to mimic the activities of polymyxin B and its derivatives, acting as potent antibiotics and effective permeabilizers of the outer membranes of gram-negative bacteria. Some compounds rival polymyxin B in antibacterial activity against gram-negative and gram-positive bacteria and can synergistically interact with hydrophobic antibiotics to inhibit bacterial growth.
Ceragenins
Synthetic small molecules designed to mimic key properties of antimicrobial peptides such as cathelicidins. Non-peptide structures offering advantages in drug development, formulation, and stability.
CAV-121
An investigational ceragenin-based therapeutic candidate being developed for Epidermolysis Bullosa, informed by innate immune biology and antimicrobial peptide-inspired science.
Services
Design and execution of in vitro and in vivo preclinical studies to evaluate antimicrobial efficacy, antibiofilm activity, and regenerative endpoints.
Formulation of small-molecule antimicrobials into micelles, gels, creams, and coatings for topical and device applications, including controlled-release testing from delivery matrices.
Development of antimicrobial coatings for medical devices (e.g., endotracheal tubes) with in vitro colonization assays and large-animal tolerability testing.
Antimicrobial susceptibility testing, biofilm assays, microscopy, spectroscopy, and nanomechanical measurements to characterize antimicrobial action and resistance profiles.
Design and execution of in vitro and in vivo preclinical studies to evaluate antimicrobial efficacy, antibiofilm activity, and regenerative endpoints.
Formulation of small-molecule antimicrobials into micelles, gels, creams, and coatings for topical and device applications, including controlled-release testing from delivery matrices.
Development of antimicrobial coatings for medical devices (e.g., endotracheal tubes) with in vitro colonization assays and large-animal tolerability testing.
Antimicrobial susceptibility testing, biofilm assays, microscopy, spectroscopy, and nanomechanical measurements to characterize antimicrobial action and resistance profiles.
Expertise Areas
- Antimicrobial therapeutics development
- Preclinical in vivo efficacy and safety studies
- Formulation and topical/device delivery systems
- Antifungal and antibiofilm research
Key Technologies
- Small-molecule mimetics of host-defense peptides
- Micellar/polymer (poloxamer) formulations
- Hydrogel/film device coatings with controlled elution
- Core-shell magnetic nanoparticles (functionalized MNPs)
News & Updates
Li, C.; Peters, A. S.; Meredith, E. L.; Allman, G. H.; Savage, P. B. J. Am. Chem. Soc. 1998, 120, 2961-2962. Design and synthesis of potent sensitizers of Gram-negative bacteria…
Ceragenins are a new class of cationic lipids characterized by a broad spectrum of bactericidal activity resulting from amphipathic nature and membrane-permeabilizing properties. CSA-13 disrupts spores formed by Bacillus subtilis, decreasing viability and resistance.
Li, C.; Peters, A. S.; Meredith, E. L.; Allman, G. H.; Savage, P. B. J. Am. Chem. Soc. 1998, 120, 2961-2962. Design and synthesis of potent sensitizers of Gram-negative bacteria…
Ceragenins are a new class of cationic lipids characterized by a broad spectrum of bactericidal activity resulting from amphipathic nature and membrane-permeabilizing properties. CSA-13 disrupts spores formed by Bacillus subtilis, decreasing viability and resistance.